Case Study: Pancreatic Adenocarcinoma

New pancreatic cancer clinic offers comprehensive care

Job # 017145 Barra 06-22-09


In October 2013, a 78-year-old male was referred to Cleveland Clinic for a discussion of treatment options for pancreatic adenocarcinoma. Over the summer, the patient had developed early satiety and loss of appetite. He had presented to his local Emergency Department one month prior with abdominal pain and jaundice. Imaging showed a mass in the pancreatic head, which was biopsied and was consistent with low-grade pancreatic adenocarcinoma. An internal/external biliary drain was placed, and the patient was sent home.


Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy


At Cleveland Clinic, the case was reviewed by members of the Pancreatic-Biliary Tumor Board before the patient was seen in our Pancreas Clinic. Solid tumor oncologist Alok Khorana, MD, and general surgeon Matthew Walsh, MD, agreed the patient was a candidate for resection. Because the typical indication for neoadjuvant chemoradiation is unresectability or borderline resectability, there was no indication for treatment prior to surgery. The patient’s imaging revealed no invasion of vascular structures, but concerns for persistent jaundice causing potential delays in initiating chemo/radiation therapy also contributed to the decision to perform surgery first. Because the risk of recurrence was very high, a minimum of six months of chemotherapy, with or without radiation, following surgery was advised.


One week later, Dr. Walsh performed an open pylorus-preserving pancreaticoduodenectomy with cholecystectomy (Whipple procedure) under general anesthesia. Pathology revealed moderately differentiated ductal adenocarcinoma, with negative margins. Sixteen lymph nodes were negative.

The patient’s postoperative course was uneventful. On postoperative day 6, a CT scan identified postoperative changes without fluid collections. His diet was advanced to soft foods and nutrition supplements to increase caloric intake. On postoperative day 7, his feeding tube was removed, along with a few staples. On day 8, the JP drain was removed, and he was discharged to a skilled nursing facility following recommendations from physical therapy for deconditioning.



Three weeks after surgery, the patient remained in rehab but was progressing well and had no need for narcotic pain medication. His appetite had improved, and he was eating solid foods. Although his cancer was early-stage, he was told that he remains at high risk for recurrence. Large randomized trials have clearly shown a benefit for adjuvant chemotherapy with gemcitabine or 5FU.

Dr. Khorana recommended a regimen of gemcitabine 1,000 mg/m2 q wk x 3 in a four-week cycle for six months. Adjuvant radiation was not recommended, given conflicting data regarding its benefit in this setting. The patient was agreeable to adjuvant treatment, which will be arranged at a location closer to his home.

Related Articles

Fluorescent imaging during small bowel surgery
April 11, 2024/Cancer/Surgical Oncology
Fluorescence Imaging Augments Surgical Inspection and Palpation for Small Bowel Carcinoid Tumors

Study demonstrates superior visualization of occult primary lesions

microwave ablation of liver tumor
150-Watt, Single-Antenna Microwave Ablation System Demonstrates Safety and Efficacy

New device offers greater tumor control for malignant liver lesions

January 2, 2024/Cancer/Surgical Oncology
Exploring Focal Therapies for Prostate Cancer (Podcast)

Patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment

23-CNR-4274323-CQD-pagets disease of the breast
October 30, 2023/Cancer/Surgical Oncology
Paget’s Disease of the Breast a Little Understood Form of DCIS

Rare cancer presents as unresolved changes of the nipple

breast cancer
October 6, 2023/Cancer/Surgical Oncology
Surgical De-Escalation for Benign High-Risk Breast Lesions

Are we ready for ‘observation’ of lesions found on core needle biopsy?

March 11, 2022/Cancer/Surgical Oncology
Hybrid Resection of a Fast-Growing Dumbbell Schwannoma: A Case Study

Two-day procedure prevents neurologic compromise for octogenarian

Liposarcoma biopsy under microscopy zoom in different ranges
March 10, 2022/Cancer/Surgical Oncology
Sarcoma Nestled Between Esophagus, Trachea and Aortic Arch: A Case Study

Preoperative chemotherapy enables successful surgical resection

3d illustration of a cross-section of a diseased skin with melanoma that enters the bloodstream and lymphatic tract
February 24, 2022/Cancer/Surgical Oncology
New Model Based on CD8 T Cells May Distinguish ICI Responders from Non-Responders in Melanoma

Study finds high levels of a CD8 T-cell subpopulation to be predictive of ICI resistance